Products Cited in Publications Worldwide Harness Albumin as a Carrier for Delivery of Anti-HIV Drugs to Lymphatic System

Harness Albumin as a Carrier for Delivery of Anti-HIV Drugs to Lymphatic System

Zhang, Ziqian; Huang, Yixian; West III, Raymond E; Mahesh, Deepika; Oberly, Patrick J; Li, Shichen; Luo, Zhangyi; Chen, Yuang; Huang, Haozhe; Bain, Daniel J

DOI:

Abstract

The persistence of HIV reservoirs within the lymphatic system represents a significant challenge to achieving a complete cure for people with , largely due to inadequate concentrations of antiretroviral drugs (ARVs) in lymphatic tissues under current treatment regimens. Thus, developing innovative therapeutic strategies to enhance ARV concentrations in the lymphatic system may provide a paradigm shift toward an cure. Here, we describe a novel delivery strategy involving an (EB) prodrug conjugate with a model ARV (dolutegravir, DTG), designed to bind albumin with high affinity and reach lymph nodes (LNs) via albumin-mediated trans-endothelial transport through transcytosis. EB modification substantially improved the distribution of conjugated molecules to LNs throughout the body, and the hEB-DTG prodrug significantly elevated DTG concentrations in both blood and LNs over time, suggesting a promising strategy for eradicating HIV reservoir.

Keywords

; ; albumin ; lymph node ; nanomedicine

Purchased from AmBeed

Tenofovir Disoproxil

A119233201341-05-198%

Tenofovir Disoproxil

15.0/100mg

Detail
Bromo-PEG4-acid

A3427481393330-38-597%

Bromo-PEG4-acid

40.0/100mg

Detail